Factors Associated with the Development of CMV Viremia in High-Risk (D+/R-) Renal Transplant Patients on Valganciclovir Prophylaxis

被引：0
|
作者：
Limaye, A. [1 ]
Hauser, I. [2 ]
Loveless, M. [3 ]
Mu, Y. [3 ]
Blumberg, E. [4 ]
Jardine, A. [5 ]
Humar, A. [6 ]
机构：
[1] U Washington, Seattle, WA USA
[2] Goethe Univ Frankfurt, Frankfurt, Germany
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] U Penn, Philadelphia, PA USA
[5] U Glasgow, Glasgow, Lanark, Scotland
[6] U Alberta, Edmonton, AB, Canada
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2012年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
144
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [1] CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study
    Rostaing, L
    Martinet, O
    Cisterne, JM
    Icart, J
    Chabannier, MH
    Durand, D
    AMERICAN JOURNAL OF NEPHROLOGY, 1997, 17 (06) : 489 - 494
  • [2] Indefinite Valganciclovir Prophylaxis among CMV D+/R- Lung Transplant Patients Is Limited by Breakthrough CMV Infections, Toxicity and Resistance
    Clancy, C.
    Shields, R.
    Toyoda, Y.
    Bhama, J.
    Kwak, E.
    Silveira, F.
    Pilewski, J.
    Crespo, M.
    Nguyen, H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S61 - S62
  • [3] Efficacy of preemptive treatment strategy for cytomegalovirus (CMV) high-risk (D+/R-) renal transplant recipients
    Ruesch, M.
    Weber, M.
    Seebach, J. D.
    Wuethrich, R. P.
    Mueller, N. J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S19 - S20
  • [4] Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
    Humar, A
    Mazzulli, T
    Moussa, G
    Razonable, RR
    Paya, CV
    Pescovitz, MD
    Covington, E
    Alecock, E
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) : 1065 - 1070
  • [5] Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D plus /R-) Lung Transplant Recipients
    Herrera, S.
    Khan, B.
    Husain, S.
    Binnie, M.
    Chow, C.
    Martinu, T.
    Chaparro, C.
    Keshavjee, S.
    Singer, L. G.
    Tikkanen, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S120 - S120
  • [6] Clinical outcomes of valganciclovir prophylaxis in high-risk (D plus /R-) renal transplant recipients experiencing delayed graft function
    Freedman, Sari R.
    Ravichandran, Bharath R.
    Masters, Brian M.
    Bromberg, Jonathan S.
    Haririan, Abdolreza
    Saharia, Kapil K.
    Heil, Emily L.
    Sparkes, Tracy
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (04)
  • [7] ECONOMIC EVALUATION OF THE EXTENSION OF PROPHYLAXIS AGAINST CMV FROM 100 TO 200 DAYS IN RENAL TRANSPLANT RECIPIENTS AT HIGH RISK (D+/R-)
    Morales Buenrostro, L. E.
    VALUE IN HEALTH, 2011, 14 (07) : A559 - A560
  • [8] Prophylactic Therapy With Valganciclovir in High-Risk (Cytomegalovirus D+/R-) Kidney Transplant Recipients: A Single-Center Experience
    Montejo, M.
    Porto, M.
    Carmon, O.
    Zarraga, S.
    Gainza, J.
    Amenabar, J. J.
    Goikoetxea, J.
    Bereciartua, E.
    Lampreabe, I.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (08) : 2947 - 2949
  • [9] Oral ganciclovir and valganciclovir prophylaxis may prevent reactivation of non-β herpesviruses in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients
    Razonable, RR
    Brown, RA
    Humar, A
    Covington, E
    Alecock, E
    Paya, CV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 337 - 337
  • [10] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
12345